538 related articles for article (PubMed ID: 28315051)
1. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
Gu J; Al-Bayati K; Ho EA
Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
[TBL] [Abstract][Full Text] [Related]
2. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
3. Targeted siRNA delivery by anti-HER2 antibody-modified nanoparticles of mPEG-chitosan diblock copolymer.
Wang Y; Liu P; Du J; Sun Y; Li F; Duan Y
J Biomater Sci Polym Ed; 2013; 24(10):1219-32. PubMed ID: 23713424
[TBL] [Abstract][Full Text] [Related]
4. T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles.
Lee J; Yun KS; Choi CS; Shin SH; Ban HS; Rhim T; Lee SK; Lee KY
Bioconjug Chem; 2012 Jun; 23(6):1174-80. PubMed ID: 22607555
[TBL] [Abstract][Full Text] [Related]
5. Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers.
Raja MA; Katas H; Jing Wen T
PLoS One; 2015; 10(6):e0128963. PubMed ID: 26068222
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles.
Yang F; Huang W; Li Y; Liu S; Jin M; Wang Y; Jia L; Gao Z
Biomaterials; 2013 Jul; 34(22):5689-99. PubMed ID: 23632321
[TBL] [Abstract][Full Text] [Related]
7. Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core.
Clark AJ; Davis ME
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12486-91. PubMed ID: 26392563
[TBL] [Abstract][Full Text] [Related]
8. Carbosilane dendrimers to transfect human astrocytes with small interfering RNA targeting human immunodeficiency virus.
Jiménez JL; Clemente MI; Weber ND; Sanchez J; Ortega P; de la Mata FJ; Gómez R; García D; López-Fernández LA; Muñoz-Fernández MA
BioDrugs; 2010 Oct; 24(5):331-43. PubMed ID: 20795754
[TBL] [Abstract][Full Text] [Related]
9. Urocanic acid-modified chitosan nanoparticles can confer anti-inflammatory effect by delivering CD98 siRNA to macrophages.
Xiao B; Ma P; Viennois E; Merlin D
Colloids Surf B Biointerfaces; 2016 Jul; 143():186-193. PubMed ID: 27011348
[TBL] [Abstract][Full Text] [Related]
10. PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting.
Monsalve Y; Tosi G; Ruozi B; Belletti D; Vilella A; Zoli M; Vandelli MA; Forni F; López BL; Sierra L
Nanomedicine (Lond); 2015; 10(11):1735-50. PubMed ID: 26080696
[TBL] [Abstract][Full Text] [Related]
11. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.
Ragelle H; Riva R; Vandermeulen G; Naeye B; Pourcelle V; Le Duff CS; D'Haese C; Nysten B; Braeckmans K; De Smedt SC; Jérôme C; Préat V
J Control Release; 2014 Feb; 176():54-63. PubMed ID: 24389132
[TBL] [Abstract][Full Text] [Related]
12. Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages.
Zhang J; Tang C; Yin C
Biomaterials; 2013 May; 34(14):3667-77. PubMed ID: 23419643
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
14. Brain pharmacokinetics of neurotoxin-loaded PLA nanoparticles modified with chitosan after intranasal administration in awake rats.
Zhang X; Liu L; Chai G; Zhang X; Li F
Drug Dev Ind Pharm; 2013 Nov; 39(11):1618-24. PubMed ID: 24087853
[TBL] [Abstract][Full Text] [Related]
15. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
[TBL] [Abstract][Full Text] [Related]
16. Delivery of siRNA targeting tumor metabolism using non-covalent PEGylated chitosan nanoparticles: Identification of an optimal combination of ligand structure, linker and grafting method.
Corbet C; Ragelle H; Pourcelle V; Vanvarenberg K; Marchand-Brynaert J; Préat V; Feron O
J Control Release; 2016 Feb; 223():53-63. PubMed ID: 26699426
[TBL] [Abstract][Full Text] [Related]
17. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
[TBL] [Abstract][Full Text] [Related]
18. Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating.
Jagani HV; Josyula VR; Palanimuthu VR; Hariharapura RC; Gang SS
Eur J Pharm Sci; 2013 Mar; 48(4-5):611-8. PubMed ID: 23291045
[TBL] [Abstract][Full Text] [Related]
19. Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles.
Wei L; Guo XY; Yang T; Yu MZ; Chen DW; Wang JC
Int J Pharm; 2016 Aug; 510(1):394-405. PubMed ID: 27374198
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeting transferrin nanoparticles for systemic polymerized siRNA delivery in tumor-bearing mice.
Yhee JY; Lee SJ; Lee S; Song S; Min HS; Kang SW; Son S; Jeong SY; Kwon IC; Kim SH; Kim K
Bioconjug Chem; 2013 Nov; 24(11):1850-60. PubMed ID: 24107100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
